FWD1509 MsOH

福沃替尼

Report date: 2023/03/29 15:19:37
NME

Base Information

Drug NameFWD1509 MsOH
Drug Alias NameFWD1509 MsOH
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR exon 20 insertion mutations inhibitorsEGFR 19del inhibitorsEGFR L858R inhibitors +[4] 
TargetsEGFR exon 20 insertion mutationsEGFR 19delEGFR L858R +[4] 
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShenzhen Forward Pharmaceuticals Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShenzhen Forward Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A